TALPHERA, INC. (TLPH) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -14.75M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 6.70M USD | Research and Development Expense |
| Selling, general and administration | 8.04M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-14.75M | (m) | (m) | $6.70M | $8.04M | (m) |
| 2026-03-31 | $-14.52M | (m) | (m) | $6.51M | $8.00M | (m) |
| 2025-12-31 | $-13.48M | (m) | (m) | $6.03M | $7.48M | (m) |
| 2025-09-30 | $-13.03M | (m) | (m) | $5.79M | $7.26M | (m) |
| 2025-06-30 | $-13.35M | (m) | (m) | $6.04M | $7.34M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $6.45M | $7.50M | (m) |
| 2024-12-31 | $-15.25M | (m) | (m) | $6.72M | $8.53M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $7.16M | $9.66M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $6.29M | $10.21M | (m) |
| 2023-12-31 | $-16.89M | (m) | (m) | $5.55M | $11.99M | (m) |
| 2023-03-31 | $-37.02M | (m) | (m) | $5.40M | $25.85M | (m) |
| 2022-12-31 | $-36.63M | (m) | $2.59M | $5.19M | $25.67M | (m) |
| 2022-09-30 | $-37.38M | (m) | $3.46M | $5.15M | $25.38M | (m) |
| 2022-06-30 | $-39.38M | (m) | $3.33M | $5.26M | $28.76M | (m) |
| 2022-03-31 | $-35.82M | (m) | $3.50M | $4.44M | $30.63M | (m) |
| 2021-12-31 | $-35.97M | (m) | $3.75M | $4.09M | $30.93M | (m) |
| 2021-09-30 | $-37.03M | (m) | $3.82M | $3.94M | $32.82M | (m) |
| 2021-06-30 | $-37.44M | (m) | $5.23M | $3.48M | $31.78M | (m) |
| 2021-03-31 | $-34.26M | (m) | $5.56M | $3.57M | $30.66M | (m) |
| 2020-12-31 | $-40.96M | (m) | $6.03M | $4.02M | $36.33M | (m) |
| 2020-09-30 | $-46.71M | (m) | $6.35M | $4.24M | $41.27M | (m) |
| 2020-06-30 | $-51.21M | (m) | $6.65M | $4.35M | $44.61M | (m) |
| 2020-03-31 | $-57.73M | (m) | $7.09M | $4.70M | $48.36M | (m) |
| 2019-12-31 | $-54.20M | $2.29M | $6.81M | $4.66M | $45.03M | -2368.06% |
| 2019-09-30 | $-50.19M | (m) | $6.43M | $6.30M | (m) | (m) |
| 2019-06-30 | $-45.98M | (m) | $5.15M | $8.89M | (m) | (m) |
| 2019-03-31 | $-39.78M | (m) | $4.09M | $11.00M | (m) | (m) |
| 2018-12-31 | $-35.73M | $2.15M | $3.98M | $13.14M | (m) | -1660.95% |
| 2018-09-30 | $-32.56M | $2.28M | (m) | $14.11M | (m) | -1429.19% |
| 2018-06-30 | $-32.09M | $3.39M | (m) | $14.38M | (m) | -947.17% |
| 2018-03-31 | $-34.88M | $5.23M | (m) | $16.00M | (m) | -667.01% |
| 2017-12-31 | $-38.68M | $8.00M | (m) | $19.41M | (m) | -483.83% |
| 2017-09-30 | $-38.01M | $13.69M | (m) | $22.07M | (m) | -277.67% |
| 2017-06-30 | $-37.13M | $15.57M | (m) | $22.77M | (m) | -238.47% |
| 2017-03-31 | $-35.51M | $17.44M | (m) | $24.15M | (m) | -203.59% |
| 2016-12-31 | $-31.96M | $17.36M | (m) | $21.40M | (m) | -184.12% |
| 2016-09-30 | $-32.35M | $12.65M | (m) | $18.55M | (m) | -255.73% |
| 2016-06-30 | $-17.27M | $24.71M | (m) | $19.32M | (m) | -69.90% |
| 2016-03-31 | $-17.08M | $22.11M | (m) | $20.35M | (m) | -77.24% |
| 2015-12-31 | $-19.95M | $19.26M | (m) | $22.49M | (m) | -103.59% |
| 2015-09-30 | (m) | $17.76M | (m) | $26.29M | (m) | (m) |
| 2015-06-30 | (m) | $7.16M | (m) | $26.14M | (m) | (m) |
| 2015-03-31 | (m) | $5.30M | (m) | $26.11M | (m) | (m) |
| 2014-12-31 | (m) | $5.22M | (m) | $24.52M | (m) | (m) |
| 2014-09-30 | (m) | $32.60M | (m) | $21.56M | (m) | (m) |
| 2014-06-30 | (m) | $28.32M | (m) | $22.86M | (m) | (m) |
| 2014-03-31 | (m) | $28.66M | (m) | $21.68M | (m) | (m) |
| 2013-12-31 | (m) | $29.50M | (m) | $26.29M | (m) | (m) |
| 2013-09-30 | (m) | $3.57M | (m) | $29.77M | (m) | (m) |
| 2013-06-30 | (m) | $3.19M | (m) | $30.17M | (m) | (m) |
| 2013-03-31 | (m) | $3.00M | (m) | $29.45M | (m) | (m) |
| 2012-12-31 | (m) | $2.39M | (m) | $24.91M | (m) | (m) |
| 2012-09-30 | (m) | $1.34M | (m) | $21.82M | (m) | (m) |
| 2012-06-30 | (m) | $1.58M | (m) | $18.81M | (m) | (m) |
| 2012-03-31 | (m) | $1.40M | (m) | $16.45M | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | $13.62M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | $10.81M | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | $8.37M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |